Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 2Burkitt Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Glioblastoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Mercaptopurine × Clear all
NCT06279767 2024-02-28

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Unknown
27 enrolled
CNS

Glioblastoma, Neoplasms

NCT02912676 2020-04-15

TEAM

Rigshospitalet, Denmark

Phase 1/2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡